Samsung Biologics recognized for leadership band in water security

[Press Release] Samsung Biologics announced on February 12 that it has received 'Leadership' status and an A- rating for water security from the Carbon Disclosures Project (CDP), underscoring the company’s efficient water resources management. The company participated in the category for the first time. CDP is a non-profit organization that evaluates the corporate environmental transparency and performance of over 24,800 companies listed worldwide. The rating recognizes Samsung Biologics’ effort

HK inno.N’s K-CAB wins a landmark victory in the second-instance trial for its substance patent

[Press Release] HK inno.N, announced on Thursday (6th of February) that the company won the second-instance trial following its win in the first-instance trial related to the compound (substance) patent for its new acid-related disease treatment ‘K-CAB Tablet (K-CAB).’ Following the favorable ruling by the Intellectual Property Trial and Appeal Board (IPTAB), Intellectual Property High Court also ruled in favor of HK inno.N, the originator company, which indicates that K-CAB is granted patent pr

Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States

Pictured from left: McK Kevin Cloutier (Vice President of Sales & Business Development, McKesson Pharmacy Automation, USA), Yves Blanchette (Vice President of Technology Solutions, McKesson Canada), Hanmi Pharmaceutical Overseas Sales Team Leader Lee Ji-hyun, and McK Steve Dennison (Vice President and General Manager, McKesson Canada Automation). [Press Release] Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making significant strides in penetrating the Canadian and U

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

[Press Release] The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant attention in the field of immunotherapy. On November 25, Hanmi announced that it presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference, held in Houston, USA, from

Samsung Biologics signs manufacturing deal with European pharmaceutical company

Samsung Biologics’ cumulative contract value for 2024 surpasses USD 4 billion with latest deals [Press Release] On November 20, Samsung Biologics announced a series of manufacturing deals with a Europe-based pharmaceutical company. The disclosed deals, worth over USD 668 million combined, will run through December 2031. The latest agreements bring up the company’s cumulative contract value for this year to more than USD 4 billion. "We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals t

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation 사진=삼성바이오로직스 [Press Release] On October 14, Samsung Biologics, a global contract development and manufacturing organization (CDMO), launched a new high-concentration formulation platform to support the development and manufacturing of high-dose biopharmaceuticals. S-HiConTM can proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery. Through optimization of pH, buffer species, and excipients, along with a prelim

ST Pharm Banwol Campus Awarded EcoVadis 'Gold' Medal

[Press Release] On September 6, ST Pharm announced that its Banwol Campus has been awarded a 'Gold' medal from EcoVadis. This recognition comes five years after the company first received a 'Bronze' medal in 2019. EcoVadis is a leading global sustainability rating agency, evaluating companies from 180 countries and approximately 130,000 enterprises based on four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The agency awards medals based on performance, with

HK inno.N-IMBiologics-Y-Biologics Transfer Autoimmune Disease Drug Tech to China

$315.5 million worth of a tech transfer agreement signed for Asia including China [Press Release] On August 16, HK inno.N announced that technology of OXTIMA, an autoimmune disease antibody drug candidate jointly developed by IMBiologics and Y-Biologics, has been transferred to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. This is the second milestone for the company, following a deal with Navigator Medicines in the U.S. in June. The technology transfer agreement, led by IMBiologics, is valued at USD 315.5 million (approximately KRW 430 billion), including an upfront pay

SK bioscience and CEPI Deepen Partnership for Pandemic Prevention, Preparedness and Response

"We must work together as ONE TEAM toward a common goal, the 100 Days Mission to prepare for the next pandemic" [Press Release] SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company and the Coalition for Epidemic Preparedness Innovations (CEPI) a hosted the ´Celebrating Partnership for Pandemic Preparedness: CEPI-SK bioscience Reception’ in Yeoui-do, Seoul on August 29th. The CEPI Board and senior officials visited Korea this week to discuss global collaboration to prevent the spread of infectious diseas

ST Pharm, honored with two awards at the 'Korea Biopharma Excellence Awards 2024'

[Press Release] Experts recognize excellence in mRNA manufacturing capabilities and preventive/therapeutic vaccine development capabilities. ST Pharm announced that the company won two awards at the Korea Biopharma Excellence Awards 2024 held at Convensia in Songdo, Incheon on August 13. First, it won the ‘Bioprocessing Excellence Award in mRNA Manufacturing’ in the Bioprocessing Supplier Excellence Awards category and the 'Most Promising Therapeutic Vaccine' award in the Innovation Excellence A